Key result
Polymer-free sirolimus-eluting stents show a low ~2.2% 1-year TLR rate in all-comers.
Why the study?
The safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stents (PF-SES) in a large unselected patient population undergoing PCI were not well established.
Observational (n=7,243)
Yes
Answers are grounded in this paper and cite their sources.
Low TLR rates with polymer-free sirolimus-eluting stents in all-comers; extends real-world data but leaves open randomized confirmation.
Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates.
No takes yet. Share an insight, caveat, or question.
Krackhardt et al. (2020) conducted an observational in Stable coronary artery disease or acute coronary syndrome (n=7,243). Polymer-free sirolimus eluting stent (PF-SES) was evaluated on Accumulated target lesion revascularization (TLR) rate at 9-12 months. In a large, unselected all-comers patient population, routine clinical use of a polymer-free sirolimus-eluting stent was associated with a low accumulated target lesion revascularization rate of 2.2% at 9 to 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: